Close Menu

NEW YORK – The US Attorney's Office for the District of Massachusetts said this week that kidney dialysis firm Fresenius Medical Care Holdings has agreed to pay $5.2 million to settle allegations that it tested dialysis patients unnecessarily for hepatitis B surface antigen and then billed Medicare for the tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.